

Supplemental Material

Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)

Rebecca L. Ingram¹ · Sarah E. Weiser (ORCID iD: 0000-0002-7899-678X)¹

¹Pharmaceutical Research and Development, Pfizer Inc, Andover, MA, USA


Corresponding author: Mrs. Rebecca Ingram, Associate Research Fellow, Pharmaceutical Research and Development, Pfizer; 1 Burtt Road, Andover, MA 01810; email: rebecca.ingram@pfizer.com; phone: 1-978-247-4274

Journal name: Drugs in R&D

Contents


Supplementary Fig S1 Level of HMMS after multiple FT handling assessments	2
Supplementary Fig S2 SE-HPLC profiles of PF-06439535 and bevacizumab-US after storage at 40°C for 1 month	3
Supplementary Fig S3 iCE profiles of PF-06439535 and bevacizumab-US after storage at 40°C for 1 month.....	4
Supplementary Fig S4 Non-reducing CGE profiles of PF-06439535 and bevacizumab-US after storage at 40°C for 1 month.....	5
Supplementary Fig S5 Total subvisible particles $\geq 2 \mu\text{m/mL}$ in PF-06439535 in biosimilar formulations (succinate or histidine) or in the RP formulation (phosphate) and in bevacizumab-EU ..	6
Supplementary Table S1 Protein concentration (mg/mL) for drug products.....	7
Supplementary Table S2 pH of drug products.....	8

Supplementary Fig S1 Level of HMMS after multiple FT handling assessments




5 FT handling assessments were performed at a protein concentration of 25 mg/mL and temperatures of $-20^{\circ}\text{C}/5^{\circ}\text{C}$ and $-80^{\circ}\text{C}/5^{\circ}\text{C}$. *FT* freeze-thaw; *HMMS* high-molecular mass species; *RP* reference product

Supplementary Fig S2 SE-HPLC profiles of PF-06439535 and bevacizumab-US after storage at 40 °C for 1 month




HMMS high-molecular mass species; *LMMS* low-molecular mass species; *SE-HPLC* size-exclusion high-performance liquid chromatography

Supplementary Fig S3 iCE profiles of PF-06439535 and bevacizumab-US after storage at 40 °C for 1 month




iCE imaged capillary electrophoresis; *pI* isoelectric point

Supplementary Fig S4 Non-reducing CGE profiles of PF-06439535 and bevacizumab-US after storage at 40 °C for 1 month



CGE capillary gel electrophoresis

Supplementary Fig S5 Total subvisible particles $\geq 2 \mu\text{m/mL}$ in PF-06439535 in biosimilar formulations (succinate or histidine) or in the RP formulation (phosphate) and in bevacizumab-EU



RP reference product

Supplementary Table S1 Protein concentration (mg/mL) for drug products

RP reference product

Supplementary Table S2 pH of drug products

RP reference product